This study will examine the effectiveness and safety of raltegravir (isentress) when used
together with lopinavir/ritonavir (kaletra) for the treatment of HIV-infection. Isentress is
a recently, Food and Drug Administration (FDA) approved, HIV medication that has strong
effects against the HIV virus. Isentress has been shown in other studies to be safe and well
tolerated by HIV patients. Combining this drug with kaletra might enable us to construct a
HIV regimen that does not include the more toxic drugs of the nucleoside reverse
transcriptase inhibitor class.
Eligible volunteers will undergo the following as part of the study procedure:
1. Sign the study consent form and the HIPAA Authorization Form.
2. Two-third of subjects, the intervention group (selected by random chance) will have
their HIV drug treatment changed to kaletra + isentress.
3. The other one-third will continue their usual HIV medications (this will be the control
group).
4. Make 9 study related visits to the Ponce clinic during the 48 weeks study period. During
these visits, medical information will be collected, and blood tests will be performed.
5. Perform Dexa-scan on two separate occasions at Emory University Hospital Radiology.
Information collected will be used to assess the effectiveness of this treatment in keeping
the HIV virus suppressed, how well these two drugs together is tolerated by HIV-infected
patients, and the blood levels of these two drugs when given together.